Literature DB >> 11072606

Successful treatment of protein-losing enteropathy due to AA amyloidosis with somatostatin analogue and high dose steroid in ankylosing spondylitis.

Y S Jeong1, J B Jun, T H Kim, I H Lee, S C Bae, D H Yoo, M H Park, S Y Kim.   

Abstract

Secondary amyloidosis is an occasional complication of ankylosing spondylitis (AS) and in most cases renal amyloidosis presents with proteinuria, nephrotic syndrome and decreased renal function. We describe a 32-year-old male patient with AS manifested by frequent diarrhea, intermittent abdominal pain and low serum albumin levels. He has suffered from severe inflammatory back pain for 14 years with multiple peripheral joint involvement. Protein-losing enteropathy due to gastrointestinal amyloidosis was diagnosed with 99mTc-human albumin scintigraphy, fecal alpha-1 antitrypsin clearance and colonoscopic biopsy with Congo red staining. Somatostatin analogue octreotide and prednisolone were introduced with successful result.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072606

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  A case of rheumatoid arthritis with protein losing enteropathy induced by multiple diaphragmatic strictures of the small intestine: successful treatment by bougieing under double-balloon enteroscopy.

Authors:  Y Kamata; M Iwamoto; H Nara; T Kamimura; N Takayashiki; H Yamamoto; K Sugano; T Yoshio; H Okazaki; S Minota
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

2.  Duodenal amyloidosis secondary to ulcerative colitis.

Authors:  Seung Woon Park; Sam Ryong Jee; Ji Hyun Kim; Sang Heon Lee; Jin Won Hwang; Ji Geon Jang; Dong Woo Lee; Sang Yong Seol
Journal:  Intest Res       Date:  2018-01-18

3.  The burden of amyloidosis on the gastrointestinal tract of an ankylosing spondylitis patient.

Authors:  Levent Ozçakar; Seyfettin Köklü; Bayram Kaymak; Sedef Kuran; Zişan Sakaoğullari
Journal:  Clin Rheumatol       Date:  2003-10-16       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.